Novozymes A/S

80 articles about Novozymes A/S

• Legacy Novozymes delivers solid last full-year results

  2/1/2024

  In the 2023 financial year, legacy Novozymes delivers 5% organic sales growth – 6% organic sales growth in the fourth quarter alone – an EBIT-margin before special items[*] of 25.4%, and ROIC including goodwill before special items* of 16.5%.

• The combination of Novozymes and Chr. Hansen is now successfully completed, creating Novonesis – a leading global biosolutions partner

  1/29/2024

  On December 12, 2022, Novozymes and Chr. Hansen entered into an agreement to create a leading global biosolutions partner through a statutory merger of the two companies.

• Novozymes and Chr. Hansen announce name of future combined company; Novonesis

  12/13/2023

  Novozymes and Chr. Hansen announced their future name ‘Novonesis’. The name reflects the beginning of an era of biosolutions where Novonesis will unleash the full potential of biological solutions and generate significant value for all stakeholders and society at large.

• Novozymes launches Quara® LowP for renewable diesel feedstock pre-treatment

  11/9/2023

  As the world seeks sustainable alternatives to traditional fuels, renewable diesel and SAF production have taken center stage.

• Novozymes accelerates growth in Q3 and is on track to deliver on full-year expectations

  10/26/2023

  October 26, 2023. Novozymes delivers 5% organic sales growth, an EBIT-margin of 25.5% before special items, and ROIC including goodwill of 16.3% before special items in the first nine months of the 2023 financial year.

• Novozymes and Bactolife join forces to significantly reduce post weaning diarrhea and antibiotic use among weaner pigs

  9/4/2023

  Novozymes and the Danish industrial biotech company, Bactolife, have signed a joint development and commercialization agreement to finish development and launch the biosolution Ablacto+.

• Novozymes delivers results within expectations in the first half of 2023 and narrows the full year outlook

  8/9/2023

  Novozymes delivers 3% organic sales growth, an EBIT-margin of 25% before special items, and ROIC including goodwill of 17% before special items in the first half of the 2023 financial year.

• Novozymes delivers stronger than expected Q1 results

  4/26/2023

  In the first three months of the 2023 financial year, Novozymes delivers 5% organic sales growth, an EBIT-margin of 26.0% before special items, and ROIC including goodwill of 17.7% before special items.

• Novozymes delivers historically strong full-year results

  1/26/2023

  In the 2022 financial year, Novozymes delivers 9% organic sales growth – 11% organic sales growth in the fourth quarter alone – an EBIT-margin before special items[*] of 26.4%, and ROIC including goodwill before special items* of 17.9%.

• Novozymes and LinusBio announce collaboration to accelerate scientific discovery in Biohealth

  11/10/2022

  Novozymes, the world leader in biological solutions, and LinusBio, a leader in precision exposome sequencing, announced the companies are forming a collaboration to test a new, non-invasive technology in a clinical trial.

• Novozymes confirms upgraded guidance by strong start to Q4

  11/3/2022

  In the first nine months of the 2022 financial year, Novozymes delivers 9% organic sales growth, an EBIT-margin of 27.2%, and ROIC including goodwill of 17.8%.

• Novozymes delivers strong half year results and narrows full-year outlook upwards

  8/11/2022

  Novozymes delivers 10% organic sales growth and an EBIT-margin of 26% in the first half of the year, with 18% organic sales growth in DKK.

• Novozymes announces plan to increase prices to cover rising cost of raw materials, energy, and logistics

  3/31/2022

  Novozymes announces its plan to pass on the incurred increase in raw material, energy, and logistics costs to its customers across geographies and industries.

• Novozymes delivers strong 2021 full-year results and expects continued, solid progress in 2022

  2/1/2022

  In the 2021 financial year, Novozymes delivers 6% organic sales growth – 7% organic sales growth in the fourth quarter alone – an EBIT-margin of 26.8%, and ROIC including goodwill of 19.3%.

• Novozymes is unlocking growth by delivering strong Q3 results and increasing full-year guidance

  10/26/2021

  Novozymes delivered 7% organic sales growth in the third quarter and 6% organic sales growth in the first nine months of 2021.

• Novozymes is unlocking growth with the ambition of doubling company revenue by 2030

  9/27/2021

  Unlocking Growth – Powered by Biotech” is Novozymes’ strategy towards 2025 based on the solid foundation and successful execution of “Better Business with Biology”.

• Novozymes delivers strong Q2 results and narrows full-year guidance to the high-end of the range

  8/12/2021

  Novozymes delivered 9% organic sales growth in the second quarter and 6% organic sales growth in the first half of 2021. The company has narrowed its full-year financial guidance from previously 2-6% and now expects organic sales growth of 4-6% and an EBIT margin of ~26%, from previously 25-26%.

• 

  How Biotechnology Can Save the Planet

  4/16/2019

  There is a tendency to look at biotech as being all about developing drugs. And, of course, that is the primary focus of BioSpace. However, from time to time it’s a good idea to remind ourselves that biotech can and does have broader applications besides medicines, and can, in fact, impact our da...

• Novozymes Invites Collaboration On Global Challenges

  9/21/2017

• Novozymes And Boehringer Ingelheim Announce Strategic Collaboration In Probiotics For Poultry Hatcheries

  3/30/2017